Is It Time To Buy Lannett Company Inc (LCI) Based Off Its PE Ratio? Mon, 20 Nov 2017 21:55:05 +0000 Lannett Company Inc (NYSE:LCI) is trading with a trailing P/E of 21x, which is lower than the industry average of 23.5x. While LCI might seem like an attractive stock toRead More...
Scott+Scott, Attorneys at Law, LLP is Investigating Derivative Claims on Behalf of Shareholders of Lannett Company, Inc. (LCI) Thu, 09 Nov 2017 17:05:00 +0000 NEW YORK, Nov. 9, 2017 /PRNewswire/ -- Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether certain directors and officers of Lannett Company, Inc. ("Lannett" or the "Company") (LCI) breached their fiduciary duties to the Company and its shareholders. If you are a Lannett shareholder, you are encouraged to contact Scott+Scott for additional information. Lannett develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. On July 16, 2014, Lannett disclosed that it had received interrogatories and a subpoena from the State of Connecticut Office of the Attorney General concerning its investigation into the pricing of Digoxin, one of Lannett's generic drugs. By November 3, 2016, media outlets reported that Department of Justice ("DOJ") prosecutors were considering filing criminal charges against Lannett and several other generic pharmaceutical companies by the end of 2016 for unlawfully colluding to fix generic drug prices.
Lannett Comments On Amended Civil Complaint Wed, 01 Nov 2017 10:53:00 +0000 Lannett has reviewed the complaint and believes the price fixing allegations regarding the single product named in the complaint that Lannett sells are meritless. The company intends to vigorously defend the claims in the lawsuit.
Lannett And Celgene Enter Into Settlement And License Agreement Related To Thalomid® Mon, 30 Oct 2017 10:52:00 +0000 PHILADELPHIA, Oct. 30, 2017 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into a settlement and license agreement with Celgene Corporation that resolves patent infringement litigation in the U.S. related to Celgene's Thalomid®. The license agreement permits Lannett to manufacture and market in the U.S. its generic thalidomide product as of August 1, 2019 or earlier under certain circumstances. As mandated by the U.S. Food and Drug Administration (FDA), Thalomid® is subject to Risk Evaluation and Mitigation Strategies (REMS) program, which is designed and implemented during the commercialization of a pharmaceutical product to ensure an acceptable risk-to-benefit ratio for products that are known to exhibit specific risks.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.